Larimar Therapeutics (LRMR) EPS (Basic) (2013 - 2026)

Larimar Therapeutics (LRMR) has reported EPS (Basic) for 14 consecutive years, with -$0.33 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EPS (Basic) rose 23.82% year-over-year to -$0.33; the trailing twelve-month figure through Jun 2026 stood at -$1.69 (changed 0.25% YoY), and the FY2025 full-year result was -$2.36, down 59.37% from the prior year.
• EPS (Basic) grew to -$0.33 in Q2 2026 per LRMR's latest filing, from -$0.88 in the prior quarter.
• Across five years, EPS (Basic) topped out at -$0.17 in Q1 2023 and bottomed at -$0.88 in Q4 2025.
• Historically, EPS (Basic) has averaged -$0.41 across 5 years, with a median of -$0.39 in 2024.
• The sharpest annual moves came in 2023 and 2025: EPS (Basic) surged 64.1% in 2023, then tumbled 120.78% in 2025.
• Over 5 years, EPS (Basic) stood at -$0.41 in 2022, then advanced by 20.39% to -$0.32 in 2023, then slumped by 58.36% to -$0.51 in 2024, then sank by 71.79% to -$0.88 in 2025, then soared by 62.32% to -$0.33 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.33, -$0.88, and -$0.63 for Q2 2026, Q4 2025, and Q3 2025 respectively.